Who are Eybelis ophthalmic solution 0.002%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Netarsudil Ophthalmic, DE-117B Eye Drops, DE-117 Ophthalmic Solution, DE-117.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eybelis-ophthalmic-solution-0-002.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Eybelis ophthalmic solution 0.002% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eybelis ophthalmic solution 0.002% (Eybelis ophthalmic solution 0.002%) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rho kinase (ROCK) inhibitor. Area: Ophthalmology.

marketed Rho kinase (ROCK) inhibitor ROCK1/ROCK2 Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Eybelis ophthalmic solution 0.002% (Eybelis ophthalmic solution 0.002%) — Santen Pharmaceutical Asia Pte. Ltd.. Eybelis is a selective rho kinase inhibitor that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Eybelis ophthalmic solution 0.002% TARGET	Eybelis ophthalmic solution 0.002%	Santen Pharmaceutical Asia Pte. Ltd.	marketed	Rho kinase (ROCK) inhibitor	ROCK1/ROCK2
Netarsudil Ophthalmic	Netarsudil Ophthalmic	University of the Incarnate Word	marketed	Rho kinase inhibitor	ROCK1/ROCK2, norepinephrine transporter
DE-117B Eye Drops	DE-117B Eye Drops	Santen Pharmaceutical Co., Ltd.	phase 3	Rho kinase (ROCK) inhibitor	ROCK1/ROCK2
DE-117 Ophthalmic Solution	DE-117 Ophthalmic Solution	Santen Inc.	phase 3	Rho kinase (ROCK) inhibitor	ROCK1/ROCK2
DE-117	DE-117	Santen Inc.	phase 3	Rho kinase (ROCK) inhibitor	ROCK1/ROCK2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rho kinase (ROCK) inhibitor class)

Santen Inc. · 3 drugs in this class
Santen Pharmaceutical Asia Pte. Ltd. · 1 drug in this class
Santen Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eybelis ophthalmic solution 0.002% — Competitive Intelligence Brief. https://druglandscape.com/ci/eybelis-ophthalmic-solution-0-002. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab